# Favipiravir does not improve viral clearance in mild to moderate COVID-19 – A systematic review and meta-analysis of randomized controlled trials
> Bahar M.A.

URL kanonis: https://discover.unhas.ac.id/publications/favipiravir-does-not-improve-viral-clearance-in-mild-to-moderate-covid-19-a-syst
Jurnal / Konferensi: Heliyon
Tahun terbit: 2024
DOI: https://doi.org/10.1016/j.heliyon.2024.e29808
ISSN: 24058440
Kuartil SJR: Q1
Citations: 2

## Authors
- Bahar M.A.

## Abstract
The use of favipiravir is questionable in the treatment of outpatients with COVID-19 with mild symptoms. Moderate beneficial effects in the case of patients with moderate symptoms and inpatients should be treated with care due to the limitations of the analysed trials.

## Keywords
- Favipiravir
- Coronavirus disease 2019 (COVID-19)
- Meta-analysis
- Medicine
- 2019-20 coronavirus outbreak
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Randomized controlled trial
- Systematic review
- Intensive care medicine
- MEDLINE
- Internal medicine
- Virology
- Disease
- Chemistry
- Outbreak
- Biochemistry
- Infectious disease (medical specialty)

---
Sumber: Discover Unhas — RIMS Universitas Hasanuddin.
Saat mengutip, gunakan DOI bila tersedia atau URL kanonis di atas.